Aadi bioscience to participate in h.c. wainwright's 2nd annual precision oncology conference 2021

Los angeles, oct. 19, 2021 (globe newswire) -- aadi bioscience, inc. (“aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced that founder, chief executive officer and president, neil desai, ph.d., will present at h.c. wainwright's 2nd annual precision oncology conference, which will be held virtually.
AADI Ratings Summary
AADI Quant Ranking